Free Trial
TSE:PRN

Profound Medical 5/7/2026 Earnings Report

Profound Medical logo
C$9.42 -0.33 (-3.38%)
As of 05/8/2026 03:59 PM Eastern

Profound Medical EPS Results

Actual EPS
C$0.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Profound Medical Revenue Results

Actual Revenue
$7.42 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Profound Medical Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Profound Medical Earnings Headlines

Trump Just Named His Secret AI Project. It's Called "Golden Dawn."
Behind a hidden government lab in Tennessee, 40,000 scientists are reportedly finishing work on an AI system described as 283 trillion times more powerful than today's data centers - spanning over 700 miles. Called 'Golden Dawn,' this project could leapfrog ChatGPT, Gemini, and Grok upon launch and potentially trigger a $100 trillion reset of AI markets. Louis Navellier is naming the one stock at the center of it, down to the ticker, free through May 5th.tc pixel
CEO buying at Profound Medical (PRN)
See More Profound Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Profound Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Profound Medical and other key companies, straight to your email.

About Profound Medical

Profound Medical (TSE:PRN), together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

View Profound Medical Profile